MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Boston Scientific Corp.

Отворен

СекторЗдравеопазване

101.67 1.08

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

100.76

Максимум

101.95

Ключови измерители

By Trading Economics

Приходи

-138M

562M

Продажби

352M

4.6B

P/E

Средно за сектора

74.864

57.333

EPS

0.7

Марж на печалбата

12.322

Служители

53,000

EBITDA

-41M

1B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+18.99% upside

Дивиденти

By Dow Jones

Следващи печалби

23.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-14B

138B

Предишно отваряне

100.59

Предишно затваряне

101.67

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Boston Scientific Corp. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.04.2025 г., 12:16 ч. UTC

Печалби
Значими двигатели на пазара

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3.03.2025 г., 12:35 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5.02.2025 г., 12:23 ч. UTC

Печалби

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23.04.2025 г., 10:32 ч. UTC

Печалби

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23.04.2025 г., 10:31 ч. UTC

Печалби

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 1Q EPS 45c >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 1Q Adj EPS 75c >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 1Q Sales $4.66B >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23.04.2025 г., 10:30 ч. UTC

Печалби

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3.03.2025 г., 11:59 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3.03.2025 г., 11:58 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3.03.2025 г., 11:58 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5.02.2025 г., 21:33 ч. UTC

Печалби

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5.02.2025 г., 15:20 ч. UTC

Печалби

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5.02.2025 г., 11:39 ч. UTC

Печалби

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5.02.2025 г., 11:39 ч. UTC

Печалби

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5.02.2025 г., 11:38 ч. UTC

Печалби

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5.02.2025 г., 11:38 ч. UTC

Печалби

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q Adj EPS 70c >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q Sales $4.56B >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5.02.2025 г., 11:37 ч. UTC

Печалби

Boston Scientific 4Q EPS 38c >BSX

Сравнение с други в отрасъла

Ценова промяна

Boston Scientific Corp. Прогноза

Ценова цел

By TipRanks

18.99% нагоре

12-месечна прогноза

Среден 120.35 USD  18.99%

Висок 135 USD

Нисък 110 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за Boston Scientific Corp. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

23 ratings

22

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

95.25 / 102.37Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.